Starting a global multicenter phase III study in Schizophrenia is challenging for many reasons. Understanding the patient population, regulatory landscape, access to clinics/physicians, study drug import/export permit…
last years, many phase III studies have addressed the role of chemotherapy or chemo/biotherapy in metastatic colorectal cancer (mCRC); most of these studies planned their treatment to be continued ... discontinuation…
tyrosine kinase inhibitor. We describe the rationale and design of a Phase III, randomized, double-blind study of dacomitinib versus erlotinib in patients with advanced non-small-cell lung cancer
post-surgical stage IIB-III CM pts (Phase II/III trial). The phase II part of the study was finished after randomization of 30 pts: 19 pts received ... anti-CM cells Abs at 6 months after initiation of treatment. The…
against medium-dose IFN-α2b in stage IIB-III CM patients (CASVAC-0401 phase II-III study). Here we present the results of the phase II part of the study ... treatment of high-risk CM observed so far encourage…
greater clearing of lesions and shortened duration of antibiotic treatment. Aim: The present study compared the efficacy and safety of nadifloxacin and adapalene fixed dose combination (FDC) gel with adapalene…
kinase inhibiter, pazopanib and sunitinib are first -line treatment options. a double -blind phase III study of pazopanib 800mg daily versus placebo in a2:1 randomization of treatment -naive
infections w. PA and Atyp.Mycobact. Phase III study 2002 -2017: A multicenter study from nine European countries. Results: Phase II: Group with Anti-PA IgY: 2.35 positive PA cultures ... hospitalization will be much…
inadequately controlled with diet and exercise. Methods: A phase III, randomized, double-blind, placebo-controlled, comparative, parallel-group, multicentric clinical study conducted in India between February 2022 and…
phase II/III, randomised, placebo-controlled, multi-centre clinical trial conducted at five sites in Queensland, Australia. The investigational product, rituximab, is a monoclonal antibody against CD20. The study will
studies represent proof of concept and Phase III studies are applicable to a clinical setting. Results: Eight studies were classified as phase III diagnostic studies, four of which were methodologically
contribution in this field. Our main success has been the phase III TRIBE, a multicenter, no-profit, randomized study, that demonstrated the superiority of FOLFOXIRI in combination with bevacizumab versus ... been…
assessments have been taken into account by the GBA when making judgments. 16 phase III studies, 4 phase II studies, and 2 phase I studies were included in the submissions
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.